The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. (Q51378731)

4 April 2018

title

The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. (English)

1 reference

4 April 2018

1 reference

Anne Flint

1

1 reference

4 April 2018

Christoph Kapitza

series ordinal

2

1 reference

4 April 2018

Charlotte Hindsberger

series ordinal

3

1 reference

4 April 2018

Milan Zdravkovic

series ordinal

4

1 reference

4 April 2018

language of work or name

English

0 references

publication date

17 February 2011

1 reference

4 April 2018

published in

Advances in Therapy

1 reference

4 April 2018

volume

28

1 reference

4 April 2018

page(s)

213-226

1 reference

4 April 2018

issue

3

1 reference

4 April 2018

https://scigraph.springernature.com/pub.10.1007/s12325-010-0110-x

exact match

0 references

cites work

The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Guideline for management of postmeal glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

The incretin concept today

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Effects of GLP-1 on gastric emptying, antropyloric motility, and transpyloric flow in response to a nonnutrient liquid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Disordered gastric emptying: mechanical basis, assessment and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Gastric emptying in normal subjects--a reproducible technique using a single scintillation camera and computer system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Tetracycline treatment retards the onset and slows the progression of diabetes in human amylin/islet amyloid polypeptide transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Reduced Incretin Effect in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12325-010-0110-X

10.1007/S12325-010-0110-X

21 January 2018

Identifiers

DOI

1 reference

4 April 2018

PubMed ID

21340616

1 reference

4 April 2018